Pharmacological targeting of proteoglycans and metalloproteinases: An emerging aspect in cancer treatment

Extracellular Matrix: Pathobiology and Signaling

Volumn , Issue , 2012, Pages 785-801

  Skandalis, Spyros S ^a   Cialeli, Chrisostomi ^a   Afratis, Nikos ^a   Aletras, Alexios J ^a   Tsegenidis, Theodore ^a   Theocharis, Achilleas D ^b   Karamanos, Nikos K ^a  

^a UNIVERSITY OF PATRAS   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84957861619     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (71)

1. Almholt, K., Juncker-Jensen, A., Laerum, O. D., et al. (2008). Metastasis is strongly reduced by the matrix metalloproteinase inhibitor Galardin in the MMTV-PymT transgenic breast cancer model. Mol Cancer Ther 7, 2758-2767.
2. Arslan, F., Bosserhoff, A. K., Nickl-Jockschat, T., Doerfelt, A., Bogdahn, U., and Hau, P. (2007). The role of versican isoforms V0/V1 in glioma migration mediated by transforming growth factor-beta2. Br J Cancer 96, 1560-1568.
3. Barash, U., Cohen-Kapaln, V., Dowek, I., Sanderson, R. D., Ilan, N., and Vlodavsky, I. (2010). Proteoglycans in health and disease: new concepts for heparanase function in tumor progression and metastasis. FEBS J 277, 3890-3903.
4. Batmunkh, E., Tatrai, P., Szabo, E., et al. (2007). Comparison of the expression of agrin, a basement membrane heparan sulfate proteoglycan, in cholangiocarcinoma and hepatocellular carcinoma. Hum Pathol 38, 1508-1515.
5. Berdiaki, A., Zafiropoulos, A., Fthenou, E., et al. (2008). Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines. Biochim Biophys Acta 1780, 194-202.
6. Betz, M., Huxley, P., Davies, S. J., et al. (1997). 1.8-Acrystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile. Eur J Biochem 247, 356-363.
7. Biglari, A., Bataille, D., Naumann, U., et al. (2004). Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther 11, 721-732.
8. Bix, G., Castello, R., Burrows, M., et al. (2006). Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 98, 1634-1646.
9. Bloushtain, N., Qimron, U., Bar-Ilan, A., et al. (2004). Membrane-associated heparan sulfate proteoglycans are involved in the recognition of cellular targets by NKp30 and NKp46. J Immunol 173, 2392-2401.
10. Brew, K., and Nagase, H. (2010). The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803, 55-71.
11. Brown, P. D. (2000). Ongoing trials with matrix metalloproteinase inhibitors. Expert Opin Investig Drugs 9, 2167-2177.
12. Catalgol, B., Ziaja, I., Breusing, N., et al. (2009). The proteasome is an integral part of solar ultraviolet A radiation-induced gene expression. J Biol Chem 284, 30076-30086.
13. Coxon, F. P., Thompson, K., and Rogers, M. J. (2006). Recent advances in understanding the mechanism of action of bisphosphonates. Curr Opin Pharmacol 6, 307-312.
14. Devy, L., Huang, L., Naa, L., et al. (2009). Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis. Cancer Res 69, 1517-1526.
15. Falardeau, P., Champagne, P., Poyet, P., Hariton, C., and Dupont, E. (2001). Neovastat, a naturally occuring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 28, 620-625.
16. Gialeli, C., Theocharis, A. D., and Karamanos, N. K. (2011). Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J 278, 16-27.
17. Goffin, L., Seguin-Estevez, Q., Alvarez, M., Reith, W., and Chizzolini, C. (2010). Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. Arthritis Res Ther 12, R73.
18. Goldoni, S., and Iozzo, R. V. (2008). Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int J Cancer 123, 2473-2479.
19. Goldoni, S., Seidler, D. G., Heath, J., et al. (2008). An anti-metastatic role for decorin in breast cancer. Am J Pathol 173, 844-855.
20. Hadler-Olsen, E., Fadness, B., Sylte, I., Uhlin-Hansen, L., and Winberg, J. O. (2011). Regulation of matrix metalloproteinase activity in health and disease. FEBS J 278, 28-45.
21. Hippo, Y., Watanabe, K., Watanabe, A., et al. (2004). Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 64, 2418-2423.
22. Ikeda, H., Hideshima, T., Fulciniti, M., et al. (2009). The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res 15, 4028-4037.
23. Iozzo, R. V. (1998). Matrix proteoglycans: from molecular design to cellular function. Annu Rev Biochem 67, 609-652.
24. Iozzo, R. V., Zoeller, J. J., and Nyström, A. (2009). Basement membrane proteoglycans: modulators par excellence of cancer growth and angiogenesis. Mol Cells 27, 503-513.
25. Ishiguro, T., Sugimoto, M., Kinoshita, Y., et al. (2008). Anti-glypican-3 antibody as a potential antitumor agent for human liver cancer. Cancer Res 68, 9832-9838.
26. Kadenhe-Chiweshe, A., Papa, J., McCrudden, K. W., et al. (2008). Sustained VEGF blockade results in microenvironmental sequestration of VEGF by tumors and persistent VEGF receptor-2 activation. Mol Cancer Res 6, 1-9.
27. Koninger, J., Giese, N. A., di Mola, F. F., et al. (2004). Overexpressed decorin in pancreatic cancer: potential tumor growth inhibition and attenuation of chemotherapeutic action. Clin Cancer Res 10, 4776-4783.
28. Kousidou, O. C., Mitropoulou, T. N., Roussidis, A. E., Kletsas, D., Theocharis, A. D., and Karamanos, N. K. (2005). Genistein suppresses the invasive potential of human breast cancer cells through transcriptional regulation of metalloproteinases and their tissue inhibitors. Int J Oncol 26, 1101-1109.
29. Kousidou, O. Ch., Berdiaki, A., Kletsas, D., et al. (2008). Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncol 2, 223-232.
30. Kruger, A., Arlt, M. J., Gerg, M., et al. (2005). Antimetastatic activity of a novel mechanism-based gelatinase inhibitor. Cancer Res 65, 3523-3526.
31. Liotta, L. A., Tryggvason, K., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. (1980). Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284, 67-68.
32. Macaulay, V. M., O'Byrne, K. J., Saunders, M. P., et al. (1999). Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions. Clin Cancer Res 5, 513-520.
33. Mendelsohn, J., and Baselga, J. (2000) The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565.
34. Misra, S., Heldin, P., Hascall, V. C., et al. (2011). Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 278, 1429-43.
35. Mitropoulou, T. N., Tzanakakis, G. N., Kletsas, D., Kalofonos, H. P., and Karamanos, N. K. (2003). Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells. Int J Cancer 104, 155-160.
36. Moss, M. L., and Bartsch, J. W. (2004). Therapeutic benefits from targeting of ADAM family members. Biochemistry 43, 7227-7235.
37. Murphy, G., and Nagase, H. (2011). Localising MMP activities in the pericellular environment. FEBS J 278, 2-15.
38. Nakatsura, T., Kageshita, T., Ito, S., et al. (2004). Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 10, 6612-6621.
39. Nash, M. A., Deavers, M. T., and Freedman, R. S. (2002). The expression of decorin in human ovarian tumors. Clin Cancer Res 8, 1754-1760.
40. Nash, M. A., Loercher, A. E., and Freedman, R. S. (1999). In vitro growth inhibition of ovarian cancer cells by decorin: synergism of action between decorin and carboplatin. Cancer Res 59, 6192-6196.
41. Navon, A., and Ciechanover, A. (2009). The 26 S proteasome: from basic mechanisms to drug targeting. J Biol Chem 284 (49), 33713-33718.
42. Nikitovic, D., Berdiaki, A., Zafiropoulos, A., et al. (2008). Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. FEBS J 275, 350-361.
43. Nutt, C. L., Zerillo, C. A., Kelly, G. M., and Hockfield, S. (2001). Brain enriched hyaluronan binding (BEHAB)/brevican increases aggressiveness of CNS-1 gliomas in Lewis rats. Cancer Res 61, 7056-7059.
44. Pfaffen, S., Frey, K., Stutz, I., Roesli, C., and Neri, D. (2010) Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3. Eur J Nucl Med Mol Imaging 37 (8), 1559-1565.
45. Reunanen, N., Li, S. P., Ahonen, M., Foschi, M., Han, J., and Kähäri, V. M. (2002). Activation of p38 alpha MAPK enhances collagenase-1 (matrix metalloproteinase (MMP)-1) and stromelysin-1 (MMP-3) expression by mRNA stabilization. J Biol Chem 277, 32360-32368.
46. Richardson, P. G., Barlogie, B., Berenson, J., et al. (2003). A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348, 2609-2617.
47. Rodrigues, D. B., Chammas, R., Malavasi, N. V., et al. (2010). Anti-tumor therapy with macroencapsulated endostatin producer cells. BMC Biotechnol 10, 19.
48. Santra, M., Mann, D. M., Mercer, E. W., Skorski, T., Calabretta, B., and Iozzo, R. V. (1997). Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J Clin Invest 100, 149-157.
49. Sapadin, A. N., and Fleischmajer, R. (2006). Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 54, 258-265.
50. Schaefer, L., and Schaefer, R. M. (2010). Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res 339, 237-246.
51. Seto, A. G. (2010). The road toward microRNA therapeutics. Int J Biochem Cell Biol 42, 1298-1305.
52. Shimizu-Hirota, R., Sasamura, H., Mifune, M., et al. (2001). Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors. J Am Soc Nephrol 12, 2609-2615.
53. Sidera, K., Gaitanou, M., Stellas, D., Matsas, R., and Patsavoudi, E. (2008). A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2. J Biol Chem 283, 2031-2041.
54. Skandalis, S. S., Aletras, A. J., Gialeli, C., et al. (2012). Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules. Curr Mol Med, in press.
55. Stellas, D., Hamidieh, A., and Patsavoudi, E. (2010). Monoclonal antibody 4C5 prevents activation of MMP2 and MMP9 by disrupting their interaction with extracellular HSP90 and inhibits formation of metastatic breast cancer cell deposits. BMC Cell Biol 11, 51.
56. Stellas, D., Karameris, A., and Patsavoudi, E. (2007). Monoclonal antibody 4C5 immunostains human melanomas and inhibits melanoma cell invasion and metastasis. Clin Cancer Res 13, 1831-1838.
57. Steward, W.P., and Thomas, A., L. (2000). Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert Opin Investig Drugs 9, 2913-2922.
58. Sund, M., and Kalluri, R. (2009). Tumor stroma derived biomarkers in cancer. Cancer Metastasis Rev 28, 177-183.
59. Syrokou, A., Tzanakakis, G. N., Hjerpe, A., and Karamanos N. K. (1999). Proteoglycans in human malignant mesothelioma. Stimulation of their synthesis induced by epidermal, insulin and platelet-derived growth factors involves receptors with tyrosine kinase activity. Biochimie 81, 733-744.
60. Tatrai, P., Dudas, J., Batmunkh, E., et al. (2006) Agrin, a novel basement membrane component in human rat and liver, accumulates in cirrhosis and hepatocellular carcinoma. Lab Invest 86, 1149-1160.
61. Theocharis, A. D. (2008). Versican in health and disease. Connect Tissue Res 49, 230-234.
62. Theocharis, A. D., Skandalis, S. S., Tzanakakis, G. N., and Karamanos, N. K. (2010). Proteoglycans in health and disease: novel roles for proteoglycan in malignancy and their pharmacological targeting. FEBS J 277, 3904-3923.
63. Tralhao, J. G., Schaefer, L., Micegova, M., et al. (2003). In vivo selective and distant killing of cancer cells using adenovirus mediated decorin gene transfer. FASEB J 17, 464-466.
64. Troup, S., Njue, C., Kliewer, E. V., et al. (2003). Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin Cancer Res 9, 207-214.
65. Viapiano, M. S., Bi, W. L., Piepmeier, J., Hockfield, S., and Matthews, R. T. (2005). Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res 65, 6726-6733.
66. Vuillermoz, B., Khoruzhenko, A., D'Onofrio, M. F., et al. (2004). The small leucine-rich proteoglycan lumican inhibits melanoma progression. Exp Cell Res 296, 294-306.
67. Wight, T. N. (2002). Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14, 617-623.
68. Wu, H.-M., Chi, K.-H., and Lin, W.-W. (2002). Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Lett 526, 101-105.
69. Zeltz, C., Brezillon, S., Perreau, C., Ramont, L., Maquart, F.-X., and Wegrowski, Y. (2009). Lumcorin: a leucine-rich repeat 9-derived peptide from human lumican inhibiting melanoma cell migration. FEBS Lett 583, 3027-3032.
70. Zeng, C., Toole, B. P., Kinney, S. D., Kuo, J. W., and Stamenkovic, I. (1998). Inhibition of tumor growth in vivo by hyaluronan oligomers. Int J Cancer 77, 396-401.
71. Zhu, A. X., Gold, P. J., El-Khoueiry, A. B., Abrams, T. A., Morikawa, H., and Philip, P. A. (2011). A phase 1 study of GC33, a recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. J Clin Oncol 29 (Suppl.), abstr 4085.